All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drdrewtimmermans on TikTok · 119s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drdrewtimmermans's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00All right, gonna work through some math here
  2. 0:02to help you out with this one.
  3. 0:03So if we have a 10 milligram vial to start out,
  4. 0:06we need to obviously add some back-period static water
  5. 0:09to that.
  6. 0:10So on average, we are usually making our BPC and our TB-500
  7. 0:14anywhere between two milligrams and three milligrams
  8. 0:17per ML, or 2000 micrograms and 3000 micrograms per ML.
  9. 0:22Now, this is one of the reasons I don't like peptide blends
  10. 0:24because they often don't get the ratios correct.
  11. 0:27And so we have to make some adjustments here.
  12. 0:29So at a 10 milligram vial, you could take five MLs
  13. 0:32of back-period static water and add to the 10 milligrams
  14. 0:35of the powder, which will make a two milligram per ML vial.
  15. 0:40So you'll have two milligrams of BPC
  16. 0:42and two milligrams of the TB-500.
  17. 0:45As long as this file here is 10 milligrams,
  18. 0:4710 milligrams and not five milligrams, five milligrams.
  19. 0:50If it's that, then it would be different.
  20. 0:52So we'll assume that it's a 10 milligrams in each.
  21. 0:57And so we now have 2000 micrograms per ML.
  22. 1:01And so if we're gonna try and get the appropriate dose
  23. 1:04of TB-500, which is generally a little bit higher dose
  24. 1:08than the BPC-157, we're gonna set that as our dosing point.
  25. 1:11And so if we want, let's say 500 micrograms of the TB-500,
  26. 1:15now we're gonna be doing 25 units,
  27. 1:18which will give us 500 micrograms of BPC-157
  28. 1:21and 500 micrograms of TB-500.
  29. 1:24Now again, that's why I don't really like these blends
  30. 1:26because we don't need to go that high very often
  31. 1:29in our patients on BPC-157.
  32. 1:32Normally we're starting out around 250,
  33. 1:34maybe 300 micrograms when we're doing a sub-Q.
  34. 1:37And so that would require less,
  35. 1:39but because we have the TB-500 in there,
  36. 1:42we wanna make sure we're getting an effective dose of that.
  37. 1:44We then have to up the dose.
  38. 1:46And so on your one ML insulin syringe,
  39. 1:49you'd be then doing 0.25 MLs,
  40. 1:52which is the same as 25 units
  41. 1:54in order to get 500 micrograms of BPC
  42. 1:56and 500 micrograms of TB-500.

Dr. Drew Timmermans's BPC-157 and TB-500 dosing claims checked

Dr. Drew Timmermans

TikTok creator

98.1K viewsWatch on TikTok

Quick answer

The video demonstrates reconstitution and dosing math for a combined BPC-157 and TB-500 subcutaneous injection, targeting 500 mcg of each peptide per dose using a 2 mg/mL solution. The creator correctly identifies a formulation tension in fixed-ratio blends when the two peptides have different typical dose ranges. Neither BPC-157 nor TB-500 has an FDA-approved indication or an established human clinical dose supported by randomized controlled trial data.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksBPC-157Provider discussion

Evidence signal

Source-backed review

Regulatory reality

BPC-157 access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Dr. Drew Timmermans's BPC-157 and TB-500 dosing claims checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

BPC-157 is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this bpc-157 video claims cluster

Best for searchers trying to separate BPC-157 research signals from overconfident recovery claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Dr. Drew Timmermans's BPC-157 and TB-500 dosing claims checked" from Dr. Drew Timmermans. We read the clip as a Peptide social video fact-checks claim about BPC-157, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video demonstrates reconstitution and dosing math for a combined BPC-157 and TB-500 subcutaneous injection, targeting 500 mcg of each peptide per dose using a 2 mg/mL solution.

The reason this review is not generic is the source wording and the canonical claim label "peptides replying to junk trades dosing for blend of bpc157 and tb50." In this clip, the useful excerpt is: "All right, gonna work through some math here to help you out with this one." That wording changes the review because it points to BPC-157 safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Multifunctionality and Possible Medical Application of the BPC 157 Peptide (2025), Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing (2019), and Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025), plus the creator's own wording. BPC-157 still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

BPC-157 has no completed human clinical trials as of 2024.
People who land here are usually comparing the BPC-157 claim with [object Object].
The strongest next step is to compare the claim with FormBlends' BPC-157 guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video demonstrates reconstitution and dosing math for a combined BPC-157 and TB-500 subcutaneous injection, targeting 500 mcg of each peptide per dose using a 2 mg/mL solution.

FormBlends verdict

BPC-157 safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the BPC-157 guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video demonstrates reconstitution and dosing math for a combined BPC-157 and TB-500 subcutaneous injection, targeting 500 mcg of each peptide per dose using a 2 mg/mL solution. The creator correctly identifies a formulation tension in fixed-ratio blends when the two peptides have different typical dose ranges. Neither BPC-157 nor TB-500 has an FDA-approved indication or an established human clinical dose supported by randomized controlled trial data.
  • The reconstitution math in this video is arithmetically correct: 10 mg in 5 mL yields 2 mg/mL, and 0.25 mL of that delivers 500 mcg per peptide.
  • BPC-157 has no completed human clinical trials as of 2024. Dose figures like 250-500 mcg reflect practitioner convention, not controlled trial data.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • BPC-157 decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the BPC-157 guide, cost path, safety notes, and provider review before acting.

Review BPC-157

What You'll Learn

  • The reconstitution math in this video is arithmetically correct: 10 mg in 5 mL yields 2 mg/mL, and 0.25 mL of that delivers 500 mcg per peptide.
  • BPC-157 has no completed human clinical trials as of 2024. Dose figures like 250-500 mcg reflect practitioner convention, not controlled trial data.
  • TB-500 (thymosin beta-4 fragment) has limited human safety data from wound care studies (Goldstein et al., 2012, Annals of the New York Academy of Sciences), but not from subcutaneous self-injection for recovery.
  • A 2021 JAMA Internal Medicine analysis by Swartz et al. found compounded medications frequently deviate from labeled concentrations, which makes precise dosing math unreliable if sourcing and purity are not verified.
  • Fixed-ratio peptide blends create a genuine clinical problem: optimizing for one peptide's dose automatically over- or under-doses the other, a concern the creator raises validly.
  • Xu et al. (2020, Journal of Pharmaceutical and Biomedical Analysis) identified notable impurity profiles in commercially sourced research peptides, a risk factor the video does not address.
  • Neither BPC-157 nor TB-500 is FDA-approved for any indication. Use outside a supervised clinical setting with quality-verified compounded product carries unquantified risk.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drdrewtimmermans actually say?

The creator walked through reconstitution math for a combined BPC-157 and TB-500 vial, landing on 500 micrograms of each peptide per injection using a 0.25 mL draw from a 2 mg/mL solution. He also flagged a real concern: blended vials lock you into fixed ratios that may not suit how each peptide is typically dosed individually.

Specifically, he argued that "the appropriate dose of TB-500 is generally a little bit higher dose than the BPC-157," which drives his math. He recommended starting BPC-157 at "250, maybe 300 micrograms" for subcutaneous use but acknowledged the blend forces a higher BPC-157 dose to hit an effective TB-500 threshold. He assumed the vial contains 10 mg of each peptide, not a 5/5 split, and built his calculations on that assumption.

Does the science back this up?

Partially, but the evidence base here is thin enough that "the science" is doing a lot of heavy lifting. Most of what exists comes from animal studies, and human clinical data on dosing for either peptide is effectively nonexistent in peer-reviewed literature.

BPC-157 (body protection compound) has been studied primarily in rodent models. Sikiric et al. (2018, Current Pharmaceutical Design) documented wound healing and anti-inflammatory effects in rats at doses that do not translate directly to human equivalents. TB-500, a synthetic fragment of thymosin beta-4, has some human safety data from wound care trials, but those used topical or systemic administration in clinical settings, not subcutaneous self-injection at the doses discussed here (Goldstein et al., 2012, Annals of the New York Academy of Sciences). There is no peer-reviewed consensus on what "an effective dose" of either compound looks like in healthy humans seeking recovery or optimization. The dosing figures circulating in telehealth and online communities are largely derived from practitioner experience, not controlled trials.

What did they get wrong (or right)?

The reconstitution math itself is correct. Five mL of bacteriostatic water added to a 10 mg vial yields a 2 mg/mL (2000 mcg/mL) solution. Drawing 0.25 mL from that delivers 500 mcg. That arithmetic checks out cleanly.

His concern about blended peptides is legitimate and worth taking seriously. If BPC-157 is typically dosed lower than TB-500, a fixed-ratio blend creates a real clinical tension: you either underdose TB-500 or overdose BPC-157. That is a genuine formulation problem, not just a preference.

What he got wrong, or at least glossed over, is the framing of 500 mcg as an "appropriate" TB-500 dose. There is no clinical trial establishing that figure in humans for the use cases being implied here. He also does not address purity, peptide degradation, or the sourcing problem: compounded peptides vary significantly in quality (Xu et al., 2020, Journal of Pharmaceutical and Biomedical Analysis found notable impurity profiles in commercially sourced research peptides). Presenting dosing math with this level of confidence implies a precision the underlying evidence does not support.

What should you actually know?

The math in this video is arithmetically sound, but math is the easy part. The harder questions are whether these doses are safe, effective, or appropriate for any given person, and those questions do not have clean answers yet.

Both BPC-157 and TB-500 remain unapproved by the FDA for any therapeutic indication. BPC-157 has no completed human clinical trials as of 2024. TB-500 has slightly more human data, but it comes from wound care contexts, not subcutaneous self-administration for athletic recovery. The compounded peptide market operates in a regulatory gray zone, and quality control is inconsistent. A 2021 analysis by Swartz et al. (JAMA Internal Medicine) found that compounded medications frequently deviate from labeled concentrations, a problem that makes precise dosing math somewhat academic if the starting material is not reliably pure. Anyone considering these compounds should be working with a licensed provider who can monitor for adverse effects, not following dosing math from a short-form video, however well-intentioned.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Drew Timmermans · TikTok creator

98.1K views on this video

Replying to @junk_trades Dosing for blend of BPC157 and TB500

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the reconstitution math in this video?

The reconstitution math in this video is arithmetically correct: 10 mg in 5 mL yields 2 mg/mL, and 0.25 mL of that delivers 500 mcg per peptide.

What does the video say about bpc-157 has no completed human clinical trials as of 2024.?

BPC-157 has no completed human clinical trials as of 2024. Dose figures like 250-500 mcg reflect practitioner convention, not controlled trial data.

What does the video say about tb-500 (thymosin beta-4 fragment) has limited human safety data from?

TB-500 (thymosin beta-4 fragment) has limited human safety data from wound care studies (Goldstein et al., 2012, Annals of the New York Academy of Sciences), but not from subcutaneous self-injection for recovery.

What does the video say about a 2021 jama internal medicine analysis by swartz et al.?

A 2021 JAMA Internal Medicine analysis by Swartz et al. found compounded medications frequently deviate from labeled concentrations, which makes precise dosing math unreliable if sourcing and purity are not verified.

What does the video say about fixed-ratio peptide blends create a genuine clinical problem: optimizing for?

Fixed-ratio peptide blends create a genuine clinical problem: optimizing for one peptide's dose automatically over- or under-doses the other, a concern the creator raises validly.

What does the video say about xu et al. (2020, journal of pharmaceutical?

Xu et al. (2020, Journal of Pharmaceutical and Biomedical Analysis) identified notable impurity profiles in commercially sourced research peptides, a risk factor the video does not address.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr. Drew Timmermans, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.